Home » US FDA to Combine Two Diabetes Drug Development Guidances
US FDA to Combine Two Diabetes Drug Development Guidances
November 17, 2010
The U.S. Food and Drug Administration (FDA) will merge two guidances — a draft guidance on developing diabetes drugs and a final guidance on evaluating risk in those drugs — and issue a combined document for industry.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor